Skip to main content
Premium Trial:

Request an Annual Quote

Caliper Posts 11 Percent Q4 Organic Growth

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Caliper Life Sciences reported after the close of the market Wednesday that its fourth-quarter revenues declined 4 percent year over year, but were up 11 percent on an organic basis.

The Hopkinton, Mass.-based firm brought in total revenues of $36.2 million for the three-month period ended Dec. 31, compared to $37.7 million for the fourth quarter of 2009. However, the company noted that excluding the impact of divestitures and a 2 percent negative impact from currency changes, its revenues were up 11 percent year over year. It also beat analysts' consensus estimate of $36.1 million.

Caliper reported product revenue of $25.1 million for the quarter, compared to $25.4 million for Q4 2009. Its service revenue was $8.1 million, up from $7.7 million, and its license fees and contract revenue was $3 million versus $4.6 million year over year.

The firm reported a 12 percent increase in revenues for its imaging products to $17.9 million from $16 million. Its LabChip revenues for the quarter dropped 16 percent to $7.7 million from $9.1 million, and its Automation products revenues fell 22 percent to $7.2 million from $9.2 million. However, on an organic basis, Automation revenues rose 9 percent year over year.

Caliper posted a GAAP net loss of $1.4 million, or $.03 per share, compared to a profit of $5.9 million, or $.11 per share, for the fourth quarter of 2009. On an adjusted basis, Caliper had net income of $1.3 million, or $.02 per share, versus $2.5 million, or $.05 per share, for Q4 2009. Analysts, on average, had called for EPS of $.01.

Its R&D spending increased 9 percent to $4.9 million from $4.5 million, while its SG&A spending climbed 9 percent to $12.7 million from $11.7 million.

"We exceeded all of our key financial objectives for 2010, including revenue, cash, and earnings improvement," Caliper President and CEO Kevin Hrusovsky said in a statement. "Other strategic developments in 2010 included our acquisition of Cambridge Research & Instrumentation … the divestiture of the last of our non-core automation product lines, and the signing of product collaboration agreements with Illumina, Sony, and Agilent."

For full-year 2010, Caliper had revenues of $123.7 million, down from $130.4 million, but just ahead of analysts' expectations of $123.6 million. Imaging revenues were up 17 percent to $60.6 million for the year versus $51.8 million for 2009, while LabChip revenues increased 6 percent to $29.7 million from $28 million, and Automation revenues dropped 27 percent to $25.5 million from $34.7 million.

The firm's revenues for the quarter and year were affected by divestitures. In May, Caliper sold its RapidTrace solid phase extraction and TurboVap evaporation product lines to Biotage for $16.5 million in cash. That deal came several months after the firm sold its Xenogen Biosciences subsidiary to Taconic Farms for about $11 million.

Its net income for the year was $4.3 million, or $.08 per share, compared to a net loss of $8.2 million, or $.17 per share, for 2009. On an adjusted basis, its profit was $960,000, or $.02 per share, versus a loss for 2009 of $5.8 million, or $.12 per share.

Caliper's R&D expenses for the year inched up to $18 million from $17.9 million, while its SG&A spending was $45.3 million, compared to $44.9 million for 2009.

Caliper finished the year with cash, cash equivalents, and marketable securities of $34.9 million.

The firm said that it expects to report full-year 2011 GAAP revenue of between $135 million and $145 million.

In early Thursday trade on the Nasdaq were down less than 1 percent at $6.53.

The Scan

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.

Study Points to Benefits of Local Consolidative Therapy, Targeted Treatments in Cancer Care

In JCO Precision Oncology, researchers report that local consolidative therapy combined with molecularly targeted treatments could improve survival for some lung cancer patients.

Genetic Variants That Lower LDL Cholesterol Linked to Reduced Heart Disease Risk

Rare variants in two genes that lower LDL cholesterol are also associated with a decreased risk of coronary heart disease, according to a new JAMA Cardiology study.

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.